University of Michigan study finds genetic sequencing could help match patients with biomarker-driven cancer trials, treatments:
NCI Cancer Center News
The University of Michigan Comprehensive Cancer Center and Michigan Center for Translational Pathology recently completed a pilot study aimed at solving the practical challenges involved in quickly and systematically sequencing genetic material from patients with advanced or treatment-resistant cancer in order to match them with existing clinical trials based on the biomarkers identified… The exploratory study, known as the Michigan Oncology Sequencing Project, found that identifying a patient’s “mutational landscape” provides a promising approach for identifying which trials may best help a patient, the researchers say.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.